ReviewFrontiers in immunology2026
Context-dependent roles of resistin-like molecule β in mucosal defense and inflammatory diseases.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistin-like molecule β (RELMβ) is a cysteine-rich secreted protein predominantly produced by intestinal goblet cells and regulated by microbial colonization, epithelial transcriptional programs, and immune signals. At the intestinal mucosal surface, recombinant murine and human RELMβ permeabilize susceptible bacterial membranes, while genetic studies in mice support its role in maintaining spatial separation between the microbiota and the epithelium. Murine studies further implicate RELMβ in defense against selected gastrointestinal nematodes, epithelial repair, intestinal inflammation, and the microbiota-dependent establishment of oral tolerance. Beyond the intestine, RELMβ has been associated with pulmonary vascular and airway remodeling, metabolic liver disease, atherosclerosis, abdominal aortic aneurysm, and selected cancers. However, the strength of this evidence varies: most causal findings derive from rodent genetic or intervention models, whereas human evidence is based largely on tissue associations and cultured-cell experiments. Mechanistically, RELMβ may act through at least two non-exclusive modes: direct membrane disruption and modulation of host-cell responses, but the relationship between these activities remains unclear. Its physiological oligomeric state, context-specific molecular interaction partners, and cellular source in the circulation and extraintestinal lesions also remain unresolved. This review distinguishes direct RELMβ evidence from inferences based on other RELM-family proteins and proposes a compartment-interaction system framework that considers protein source, route of exposure, molecular assembly, local physicochemical conditions, and available interaction partners as potential determinants of biological outcome. This framework is presented as a testable synthesis for defining experimental priorities and assessing the biological and therapeutic relevance of RELMβ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.